Cargando…

A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study

BACKGROUND: It is 1 of the standard treatment options for metastasis pancreatic cancer to receive nab-paclitaxel (125 mg/m(2)) plus gemcitabine (1000 mg/m(2)) on days 1, 8 and 15 every 28 days. Some patients showed intolerance and inconvenience to this therapeutic regimen. Thus, we conducted this re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Chen, Meng, Lingwei, Li, Xiaofen, Cheng, Ke, Yi, Cheng, Peng, Bing, Ma, Ji, Cao, Dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Hope In Despair - New Progress in The Diagnosis and Treatment of Pancreatic Cancer Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703471/ https://www.ncbi.nlm.nih.gov/pubmed/36423238 http://dx.doi.org/10.1177/10732748221141233

Ejemplares similares

Current Treatment of Potentially Resectable Pancreatic Ductal Adenocarcinoma: A Medical Oncologist’s Perspective
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2023)

Early Diagnosis of Pancreatic Cancer: Clinical Premonitions, Timely Precursor Detection and Increased Curative-Intent Surgery
por: Søreide, Kjetil, et al.
Publicado: (2023)

Surgical Treatment of Pancreatic Cancer: Currently Debated Topics on Vascular Resection
por: Pedrazzoli, Sergio
Publicado: (2023)

Impact of Granulocyte Colony-Stimulating Factor (G-CSF) on the Outcomes of Patients With Metastatic Pancreatic Adenocarcinoma (MPA) During First-Line Treatment With FOLFIRINOX: A Single-Center Retrospective Analysis
por: Carvalho de Brito, Angelo Borsarelli, et al.
Publicado: (2023)

Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART)
por: Bryant, JM, et al.
Publicado: (2023)

SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice
por: Neesse, Albrecht, et al.
Publicado: (2014)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

A randomised controlled trial of gemcitabine hydrochloride plus S-1 combination therapy versus gemcitabine hydrochloride therapy alone in pancreatic cancer patients aged ≥75 years: a study protocol for an open-label randomised feasibility study
por: Ishii, Hiroshi, et al.
Publicado: (2018)

Compute Tomography Radiomics Analysis on Whole Pancreas Between Healthy Individual and Pancreatic Ductal Adenocarcinoma Patients: Uncertainty Analysis and Predictive Modeling
por: Wang, Shuo, et al.
Publicado: (2022)

Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer
por: Kobayashi, Satoshi, et al.
Publicado: (2022)

The Role of Myeloid-Derived Suppressor Cells in the Treatment of Pancreatic Cancer
por: Dong, Peng, et al.
Publicado: (2022)

Durable response for ampullary and duodenal adenocarcinoma with a nab‐paclitaxel plus gemcitabine ± cisplatin combination
por: Cen, Putao, et al.
Publicado: (2019)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
por: Chen, Shuling, et al.
Publicado: (2023)

Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer
por: Perez, Kimberly, et al.
Publicado: (2023)

Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma
por: Domadia, Kshitij, et al.
Publicado: (2021)

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
por: Zhu, Zhou, et al.
Publicado: (2023)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
por: Zong, Yuan, et al.
Publicado: (2020)

Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
por: Kamata, Ken, et al.
Publicado: (2023)

Effect of exercise therapy on sarcopenia in pancreatic cancer: a study protocol for a randomised controlled trial
por: Yoh, Kazunori, et al.
Publicado: (2018)

Implication of exercise interventions on sleep disturbance in patients with pancreatic cancer: a study protocol for a randomised controlled trial
por: Yoh, Kazunori, et al.
Publicado: (2018)

Feasibility and efficacy of a multicomponent exercise medicine programme in patients with pancreatic cancer undergoing neoadjuvant therapy (the EXPAN trial): study protocol of a dual-centre, two-armed phase I randomised controlled trial
por: Luo, Hao, et al.
Publicado: (2021)

Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
por: Tsujimoto, Akiko, et al.
Publicado: (2019)

The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study
por: Zhang, Feng, et al.
Publicado: (2022)

Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection
por: Wolfe, Adam R., et al.
Publicado: (2020)

Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer
por: Gharaibeh, M, et al.
Publicado: (2015)

Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
por: Ceccon, Garry, et al.
Publicado: (2020)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2016)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2016)

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial
por: Bekaii-Saab, Tanios, et al.
Publicado: (2023)

A View from the Top
por: Newsom-Davis, John
Publicado: (1994)

Looking to the Top
por: Foster, Oliver
Publicado: (1994)

High Hopes for Academic Medicine: Looking up to the Top
por: Sandford, Richard
Publicado: (1994)

A View from the Top
por: Chambers, T L
Publicado: (1994)

Looking to the Top
por: Cowan, Fiona J
Publicado: (1994)

High Hopes for Academic Medicine: A View from the Top
por: Savill, John
Publicado: (1994)

Looking to the Top
por: Parker, David R
Publicado: (1994)

A View from the Top
por: Thompson, R P H
Publicado: (1994)

A View from the Top
por: Evans, J Grimley
Publicado: (1994)

Looking to the Top
por: King, Debra
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_v7jjf6ep7im31iesmu341e30b9